Temenos SaaS Supports Flowe in Launching an Ethical Challenger Bank in Record Time
7.10.2020 10:30:00 EEST | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that Banca Mediolanum Group’s digital bank, Flowe, has gone live with Temenos Transact and Financial Crime Mitigation (FCM) delivered as SaaS. Temenos Transact core banking technology enabled Flowe to launch in just five months as Italy’s newest challenger bank aiming to disrupt the market with sustainable and ethical financial services. Flowe launched in record time on Temenos SaaS after a remote implementation during the coronavirus pandemic.
Flowe launched in June 2020 to meet the needs of younger retail banking customers who desire ethical and innovative digital banking. The digital bank provides user-friendly mobile banking experiences and aims to be more eco-friendly than traditional banks. With Temenos SaaS technology, Flowe has the agility required to bring new products to market faster and offer the personalized experiences that customers need. Temenos SaaS combined with the unique ability of the underlying technologies of Temenos Transact will enable Flowe to launch new products at a fraction of the time and differentiate the customer experience.
Flowe provides an account with an Italian IBAN without monthly fees, with the Fun account; ATM withdrawals in the Eurozone are free and the maximum account balance is €10,000. The Flowe card is made from wood that comes from certified forests and it supports reforestation in Guatemala, reduces and offsets CO2 emissions and supports local families. The bank encourages social wellbeing and builds community by enabling users to share expenses. The challenger offers 100% facial recognition onboarding and it is naturally paperless in its operations. Temenos’ API-first technology allows Flowe to cut down deployment time and costs as well as easily connect to third parties. This means that the bank can continuously innovate and update its product lines to meet the changing needs of its audience of young banking consumers.
Temenos SaaS technology enabled the bank to rapidly launch, it offers elastic scalability to support Flowe’s client growth and it dramatically reduces IT costs. Flowe has created a hyper-efficient business model based on Temenos SaaS technology, which enables Flowe to pass on the benefits to its customers.
Temenos’ AI-driven FCM offers the most complete protection against financial crime to improve resiliency and customer experience despite rising cybercrime rates due to coronavirus. Flowe will implement Temenos Payments later this year to provide instant payments in response to heightened demand. Temenos Payments will be integrated with Temenos Transact to provide seamless user experiences and market-leading cost-income ratios.
Temenos worked closely with Flowe to support a remote implementation during the coronavirus pandemic. Temenos’ SaaS technology on Microsoft Azure accelerated the project timelines so that Flowe could launch in five months and address the surge in demand for digital banking. Temenos’ Italy Model Bank provided highly localized, pre-configured banking functionality so Flowe could deploy the technology as is, without customization.
Ivan Mazzoleni, Chief Executive Officer, Flowe, commented: “We are excited to announce this strategic partnership with Temenos. Its cutting-edge technology powered our launch and now fuels our purpose to bring a new standard of sustainable banking to the European market. Temenos’ focus and unparalleled investment in innovation means Flowe will continue to benefit from the most advanced banking technology. Temenos’ SaaS technology helped us to rapidly onboard a significant number of users in a matter of days. It will continue to support our growth as we expand our customer-base and reach new markets but mainly, it will help us in our scope that is empowering people to live a meaningful, sustainable and happy life. Temenos’ open and API-first architecture will help us to continuously innovate and bring to market greener banking products and services as we build our reputation as Italy’s most sustainable digital bank.”
Max Chuard, Chief Executive Officer, Temenos, added: “Congratulations to Flowe for making this inspirational vision for a sustainable financial lifestyle a reality – we are proud to support them. Our partnership with Flowe shows the power of cloud technology and the benefits of SaaS. Temenos Transact and Temenos Financial Crime Mitigation products were remotely delivered as SaaS allowing Flowe to reap the benefits of scalability, efficiency and an elastic cost structure. Temenos is proud to support global digital banks like Flowe as they challenge the status quo and digitalize banking at pace. Temenos market-leading technology and rich expertise means that new digital banks and larger incumbents can gain the agility to innovate and grow, without the restrictions of legacy technology.”
According the recent research from The Economist Intelligence Unit, building a greenfield digital bank remains a top innovation strategy according to 35% of global bank executives.
– Ends –
About Flowe
Flowe is a newly created Benefit, pending BCorp and Carbon Neutral company of Mediolanum Group, which aims to educate young people on the issues of innovation and economic, social and environmental sustainability. In this era of infinite possibilities, where younger generations often feel uncertain about their future and unable to choose a direction, Flowe wants to give young people all the methods and tools to develop their potential and live better. Through its mobile app and the growing ecosystem of partners, Flowe aims to build a BetterBeing Economy to help young people live a more meaningful, sustainable and happy life.
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201007005045/en/
Contact information
Jessica Wolfe & Scott Rowe
Temenos Global Public Relations
Tel: +1 610 232 2793 & +44 20 7423 3857
Email: press@temenos.com
Annachiara Haerens
Flowe Public Relations
Tel: 39 3494794125
Email: annachiara.haerens@flowe.com
Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
